[Visceral leishmaniases]. / Les leishmanioses viscérales.
Rev Prat
; 54(20): 2211-6, 2004 Dec 31.
Article
en Fr
| MEDLINE
| ID: mdl-15736529
Visceral leishmaniases (VL), with spreading epidemics in India and Sudan, and sporadic cases in mediterranean basin, show clinical, therapeutical and public health aspects varying according to the geographic context. Co-infection of VL with the human immunodeficiency virus emerged in southwestern Europe and could occur in a next future in India, in Sudan, in Ethiopia or in Brazil. Today, lipid formulations of amphotericin B should be the first line drugs in Mediterranean basin. Elsewhere, pentavalent antimonials remain the cornerstone of treatment in non resistant areas, conventional amphotericin B or miltefosine being an alternative in areas of resistance to antimony.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fosforilcolina
/
Leishmaniasis Visceral
Tipo de estudio:
Incidence_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Animals
/
Child, preschool
/
Humans
/
Infant
/
Newborn
País/Región como asunto:
Africa
/
America do sul
/
Asia
/
Brasil
/
Europa
Idioma:
Fr
Revista:
Rev Prat
Año:
2004
Tipo del documento:
Article
Pais de publicación:
Francia